ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth

ANI Pharmaceuticals, Inc. ANIP topped second-quarter earnings and revenue expectations, but the quarter also exposed a softer result for Cortrophin Gel, its key growth driver. That tension matters because Cortrophin now carries more weight in the company's growth mix.

ANI kept its broader 2026 outlook intact after lowering Cortrophin guidance. The revised setup therefore puts more pressure on second-half execution, especially as the gout-focused sales expansion moves from hiring to patient-case generation.

ANIP's Q2 Beat Comes With a Cortrophin Miss

Second-quarter adjusted earnings of $2.21 per share beat the Zacks Consensus Estimate of $2.01. Revenues rose 26% year over year to $266 million and also exceeded the consensus estimate of $262.7 million.

Cortrophin revenues increased 43.5% to $117.1 million, but missed the $120.4 million consensus estimate. Rare Disease revenues of $135.8 million also fell short of the $141 million consensus mark, leaving a mixed read on ANIP's main growth engine.

ANI Cuts the 2026 Cortrophin Range

ANI lowered its 2026 Cortrophin revenue outlook to $520-$540 million from $540-$575 million. Even at the revised range, management expects 50-55% growth from 2025, showing that the product remains central to the company's expansion plan.

The company maintained total revenue guidance of $1.08-$1.14 billion, adjusted EBITDA guidance of $285-$300 million and adjusted earnings guidance of $9.19-$9.69 per share. Holding those targets steady leaves less room for another Cortrophin shortfall.

ANI Pharmaceuticals, Inc. Price and Consensus

 

 

 

 

 

 

 

 

ANI Pharmaceuticals, Inc. price-consensus-chart | ANI Pharmaceuticals, Inc. Quote

ANIP's Second-Half Math Gets More Demanding

Cortrophin generated $192.2 million in the first half of 2026. Reaching the $530 million midpoint of full-year guidance would require roughly $338 million in the second half, or about 64% of the annual total.

Management expects third-quarter Cortrophin revenues of $143-$153 million, followed by further sequential growth in the fourth quarter. That implies a clear step-up from first-half levels and makes the pace of the back-half ramp a key operating test.

ANI's Gout Sales Force Must Translate Into Cases

ANI expanded its Rare Disease sales force by 50% to about 180 representatives, with the gout-focused organization fully operational by the end of June. By the end of July, more than 95% of new representatives had generated multiple patient cases.

The company estimates about 285,000 addressable patients with acute gouty arthritis flares. That creates substantial penetration room, but the near-term issue is conversion. More than one-third of prescribers had initiated at least two cases by the end of July, an early sign the larger field force is gaining traction.

ANIP Has Backup From Iluvien and Generics

Iluvien's 2026 revenue guidance remains $78-$83 million, while Generics generated $204.5 million in the first half, up 8% year over year. ANI also launched 12 generic products through June and expects at least 15 launches for the full year.

The retina business still faces established competition. AbbVie Inc. ABBV competes through Ozurdex in diabetic macular edema and non-infectious uveitis. Regeneron Pharmaceuticals, Inc. REGN competes through Eylea and Eylea HD in diabetic macular edema. That makes execution in Iluvien important as ANI leans on multiple businesses to support its companywide outlook.

ANIP's Factor Scores Clash With Near-Term Caution

The main question is whether Cortrophin can deliver the expected second-half acceleration without forcing another reset to guidance. The unchanged broader outlook gives ANI several ways to absorb variability, but Cortrophin's rising revenue concentration increases the importance of execution.

ANIP currently has a Zacks Rank #4 (Sell). At the same time, it has a Value Score of A, Growth Score of A, Momentum Score of A and VGM Score of A. Those favorable Style Scores point to attractive value, growth and momentum characteristics, but they are designed to complement the Zacks Rank rather than override it. The #4 Rank keeps the near-term signal cautious as investors watch whether the expected Cortrophin ramp materializes. 

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research